Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Breast Cancer × Genetic Testing × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 14 Prostatic Neoplasms 9 Colorectal Neoplasms 7 Ovarian Neoplasms 5 Endometrial Neoplasms 5 Colonic Neoplasms 5 Rectal Neoplasms 4 Colorectal Neoplasms, Hereditary Nonpolyposis 4 Pancreatic Neoplasms 3 Leukemia, Myeloid, Acute 3 Brain Neoplasms 3 Wilms Tumor 2 Urogenital Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplastic Syndromes, Hereditary 2 Neoplasms, Unknown Primary 2 Neoplasm Metastasis 2 Melanoma 2 Leukemia, Myelomonocytic, Acute 2 Leukemia, Monocytic, Acute 2 Leukemia, Megakaryoblastic, Acute 2 Leukemia, Erythroblastic, Acute 2 Leukemia, Eosinophilic, Acute 2 Leukemia, Basophilic, Acute 2 Leukemia 2 Kidney Neoplasms 2 Hereditary Breast and Ovarian Cancer Syndrome 2 Hematologic Neoplasms 2 Head and Neck Neoplasms 2 Glioma 2

Interventions

Trastuzumab 33 pertuzumab 18 Docetaxel 16 pyrotinib 15 Paclitaxel 7 Capecitabine 6 tucatinib 5 Carboplatin 5 Ado-Trastuzumab Emtansine 4 trastuzumab deruxtecan 3 neratinib 3 atezolizumab 2 Protons 2 Fulvestrant 2 pegfilgrastim 1 palbociclib 1 margetuximab 1 liposomal doxorubicin 1 inavolisib 1 exemestane 1 envafolimab 1 dalpiciclib 1 Taxoids 1 Neoadjuvant Therapy 1 Metformin 1 Leuprolide 1 Letrozole 1 Isovaleryl-CoA Dehydrogenase 1 Injections 1 Hospital Information Systems 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04638725 2022-08-03

SIGHER

Institut de cancérologie Strasbourg Europe

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡